Marker Therapeutics, Inc.

Monthly Archives: May 2018

The Kite Killer – TapImmune And Marker Merger Challenges Gilead

History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
Read More

TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

TapImmune today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City.
Read More

TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

TapImmune today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel.
Read More

TapImmune Partnership with Big Pharma? If Geography and Finances are Right, says CEO

TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
Read More

TapImmune and Marker Moving Ahead on Merger with Goal of Creating New Immuno-Oncology Platform

Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
Read More

TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

TapImmune Inc. (NASDAQ: TPIV) announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. EST. The webinar will be followed by a live Q&A session.
Read More

TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

TapImmune today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Read More

Merger deal for TapImmune and Marker Therapeutics

TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Read More

TapImmune to Acquire Marker Therapeutics

TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.
Read More

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer

Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.
Read More